Personalis, Inc. (PSNL) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
the bull case· 2
8 of 8
recent reports where the move came in under the options-implied range
earnings historyimplied vs realized+1.75%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 4
22.00%
of revenue from the largest disclosed customer ModernaTX Inc
10-Kfiled Feb 26 '263
of the funds on file reporting a position in PSNL
n-portas of Jun 30 '2618
managers whose positions together make up four fifths of the reported value
13fJun 30 '263 of 23
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 6 '26 report. Not a forecast, not advice.
Of the 6 companies Personalis, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 8071, Services-Medical Laboratories, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
159 managers report a position worth $1.2B between them, and 18 of them hold 80% of it.
PSNL (Personalis, Inc.) has 0 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
Personalis, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Services-Medical Laboratories
High 16.26 at 9:30 am ET, low 15.99 at 3:15 pm ET.